Poseida Therapeutics Stock Current Asset
| PSTX Stock | USD 9.31 0.02 0.21% |
Poseida Therapeutics fundamentals help investors to digest information that contributes to Poseida Therapeutics' financial success or failures. It also enables traders to predict the movement of Poseida Stock. The fundamental analysis module provides a way to measure Poseida Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Poseida Therapeutics stock.
Total Current Assets is likely to drop to about 171.6 M in 2024. Non Current Assets Total is likely to drop to about 40.2 M in 2024. Poseida | Current Asset |
Poseida Therapeutics Company Current Asset Analysis
Poseida Therapeutics' Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Current Poseida Therapeutics Current Asset | 10.59 M |
Most of Poseida Therapeutics' fundamental indicators, such as Current Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Poseida Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Poseida Current Asset Historical Pattern
Today, most investors in Poseida Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Poseida Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Poseida Therapeutics current asset as a starting point in their analysis.
Poseida Therapeutics Current Asset |
| Timeline |
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
| Competition |
Poseida Net Tangible Assets
Net Tangible Assets |
|
In accordance with the recently published financial statements, Poseida Therapeutics has a Current Asset of 10.59 M. This is 99.51% lower than that of the Biotechnology sector and 99.0% lower than that of the Health Care industry. The current asset for all United States stocks is 99.89% higher than that of the company.
Poseida Current Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Poseida Therapeutics' direct or indirect competition against its Current Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Poseida Therapeutics could also be used in its relative valuation, which is a method of valuing Poseida Therapeutics by comparing valuation metrics of similar companies.Poseida Therapeutics is currently under evaluation in current asset category among its peers.
Poseida Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Poseida Therapeutics from analyzing Poseida Therapeutics' financial statements. These drivers represent accounts that assess Poseida Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Poseida Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Enterprise Value | 551.3M | 370.2M | 278.3M | 388.5M | 344.0M | 545.8M |
Poseida Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Poseida Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Poseida Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Poseida Fundamentals
| Return On Equity | -0.58 | ||||
| Return On Asset | -0.13 | ||||
| Profit Margin | (0.40) % | ||||
| Operating Margin | 0.28 % | ||||
| Current Valuation | 759.29 M | ||||
| Shares Outstanding | 97.47 M | ||||
| Shares Owned By Insiders | 27.64 % | ||||
| Shares Owned By Institutions | 58.48 % | ||||
| Number Of Shares Shorted | 4.61 M | ||||
| Price To Earning | 214.00 X | ||||
| Price To Book | 10.40 X | ||||
| Price To Sales | 6.03 X | ||||
| Revenue | 64.7 M | ||||
| Gross Profit | (22.41 M) | ||||
| EBITDA | (109.04 M) | ||||
| Net Income | (123.43 M) | ||||
| Cash And Equivalents | 142.56 M | ||||
| Cash Per Share | 1.66 X | ||||
| Total Debt | 85.42 M | ||||
| Debt To Equity | 1.39 % | ||||
| Current Ratio | 3.69 X | ||||
| Book Value Per Share | 0.90 X | ||||
| Cash Flow From Operations | (92.17 M) | ||||
| Short Ratio | 8.30 X | ||||
| Earnings Per Share | (0.63) X | ||||
| Price To Earnings To Growth | (0.63) X | ||||
| Target Price | 9.5 | ||||
| Number Of Employees | 350 | ||||
| Beta | 0.54 | ||||
| Market Capitalization | 909.36 M | ||||
| Total Asset | 273.88 M | ||||
| Retained Earnings | (594.29 M) | ||||
| Working Capital | 155.16 M | ||||
| Current Asset | 10.59 M | ||||
| Current Liabilities | 5.1 M | ||||
| Net Asset | 273.88 M |
About Poseida Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Poseida Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Poseida Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Poseida Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Poseida Stock Analysis
When running Poseida Therapeutics' price analysis, check to measure Poseida Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Poseida Therapeutics is operating at the current time. Most of Poseida Therapeutics' value examination focuses on studying past and present price action to predict the probability of Poseida Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Poseida Therapeutics' price. Additionally, you may evaluate how the addition of Poseida Therapeutics to your portfolios can decrease your overall portfolio volatility.